3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
100
Breast Neoplasms
74
Fallopian Tube Neoplasms
47
Multiple Myeloma
32
Carcinoma, Ovarian Epithelial
27
Neoplasms
23
Lymphoma
15
Triple Negative Breast Neoplasms
12
Sarcoma
12
Recurrence
12
Neoplasm Metastasis
12
Lymphoma, Large B-Cell, Diffuse
10
Lymphoma, Non-Hodgkin
8
Hodgkin Disease
8
Neoplasms, Plasma Cell
6
Prostatic Neoplasms
5
Burkitt Lymphoma
5
Solid Tumors
4
Sarcoma, Kaposi
4
Sarcoma, Ewing
4
Pancreatic Neoplasms
4
Lymphoma, T-Cell, Peripheral
4
Lymphoma, Mantle-Cell
4
Leiomyosarcoma
4
Endometrial Neoplasms
4
Carcinoma
4
Breast Neoplasms, Male
4
Uterine Cervical Neoplasms
3
Rhabdomyosarcoma
3
Peritoneal Neoplasms
3
Interventions
liposomal doxorubicin
1
defactinib
1
Paclitaxel
1
Letrozole
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Low Grade Serous Ovarian Cancer
×
liposomal doxorubicin
×
Clear all
NCT06072781
2026-04-02
RAMP 301
Verastem, Inc.
Phase 3
Recruiting
270 enrolled